Custom 3D High-Content Screening of Organoids for Drug Discovery

Date: This event took place on May 24, 2017

Custom webcast sponsor retains sole responsibility for content.

Watch on demand now

Over the past several years there has been a boom in concerted multidisciplinary efforts by scientists and biomedical engineers with a vision of developing 3D ex vivo tissue models of human organ function, anatomy and disease. These 3D models are referred to as organoid, organotypic, or spheroid and these terms are used interchangeably within the collective literature. Organoids have the distinct feature of self-assembly when relevant components are present such as extracellular matrix (ECM) proteins. Organoids are well documented to better recapitulate aspects of in vivo organ function and human disease.

This webcast will describe the marriage of 3D organoids and high-content screening (HCS) to discover targeted drug therapies effective against the malignant phenotype in colorectal cancer (CRC). Our CRC tumor organoid model features an innovative dual reporter of epithelial-mesenchymal transition (EMT), including: E-cadherin promoter red fluorescent protein and vimentin promoter green fluorescent protein cloned into a single pCDH1 lentiviral vector.

We will also describe a robust methodology for automated tumor organoid culture and validated 3D high-content analysis algorithms. Using these approaches we have screened a focused library of 3,000 small molecule compounds and have identified and validated hits that promote the reversion of EMT in CRC.

In this webcast, you will learn about

  • 3D tumor organoids, colorectal cancer biology and EMT biology
  • Automated 3D organoid culture methodologies for high-throughput drug discovery
  • 3D High-content analysis algorithm approaches for HCS
  • HCS using an innovative phenotypic EMT dual reporter in live CRC tumor organoids


  • Dr. Daniel V. LaBarbera, University of Colorado Anschutz Medical Campus

    Dr. Daniel V. LaBarbera, University of Colorado Anschutz Medical Campus

    Dr. LaBarbera’s laboratory is engaged in preclinical drug discovery and development aimed at translating effective therapies targeting cancer, diabetes, and microbial infection. A major focus of his research is the molecular biology controlling epithelial-mesenchymal transition (EMT) and the identification of novel therapeutics that specifically target these mechanisms.

  • Joe Trask, Senior Field Applications Scientist, PerkinElmer

    Joe Trask, Senior Field Applications Scientist, PerkinElmer

    Joe has more than 20 years’ experience in high-content and cell-based technologies, studying cancer, immunology, neurodegeneration and toxicology in academia, the pharmaceutical industry and biotechnology. He has published several research articles and book chapters in the high-content imaging field. Joe was a co-founder and first President of Society for Biomolecular Imaging and Informatics (SBI2).

  • Dr. Jayshan Carpen, Springer Nature

    Moderator: Dr. Jayshan Carpen, Springer Nature

    Jayshan is a Senior Publishing Manager for Springer Nature and oversees the custom multimedia unit. Previously he ran science events at the Royal Institution of Great Britain. He received his PhD from the University of Surrey, UK in Neurogenetics. His doctoral thesis focused on identifying polymorphisms associated with diurnal preference and circadian sleep disorders.